US Patent

US12102754 — Intranasal delivery devices

Formulation · Assigned to Shin Nippon Biomedical Laboratories Ltd · Expires 2041-10-12 · 15y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects devices for delivering powder formulations, including methods of manufacture and use.

USPTO Abstract

The present disclosure provides devices for delivery of powder formulations and methods of manufacture and use of such devices.

Drugs covered by this patent

dihydroergotamine-mesylate (DIHYDROERGOTAMINE MESYLATE)

Patent Metadata

Patent number: US12102754
Jurisdiction: US
Classification: Formulation
Expires: 2041-10-12
Drug substance claim: No
Drug product claim: Yes
Assignee: Shin Nippon Biomedical Laboratories Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.